Literature DB >> 9652509

Malignant tumors of the osteogenic matrix.

V Spina1, N Montanari, R Romagnoli.   

Abstract

This article focuses on major clinical and imaging features that are of practical interest in the diagnosis and management of osteosarcoma, a malignant tumor arising from the osteogenic matrix. The current histologic classification of this tumor is also reported. Different types of osteosarcoma are described, each of them with a definite clinical and radiographic pattern. Conventional radiography is the keystone to diagnosis because it allows analysis of the patterns relevant to the different lesions (location, site, bone destruction, periostal reaction, soft tissue masses). The most common type of osteosarcoma is defined classic or conventional high grade (75%) and it typically involves the medullary cavity. Radiographically, it may be predominantly osteosclerotic or osteolytic, but more frequently it has a mixed (osteoslerotic/osteolytic) pattern. The teleangiectatic osteosarcoma is an aggressive form (5%) characterized by marked vascularization with large blood-filled cystic cavities; its typical radiographic pattern is purely osteolytic. Juxtacortical osteosarcoma (8-10%) indicates a group of osteosarcomas apparently arising on bone surface. The most common type is parosteal osteosarcoma which affects older subjects and has a better prognosis than the classic type. Radiography shows a heavily ossified mass with a broad base attached to the underlying cortex. CT and MRI are useful in the differential diagnosis of osteosarcoma and myositis ossificans or osteocondroma. Rare types of osteosarcoma include the periosteal and high-grade surface variants, as well as secondary and multifocal osteosarcoma (osteosarcomatosis). CT and MRI are the imaging procedures of choice in locoregional staging (intraosseous and extraosseous spread, skip metastases, growth plate and articular involvement). CT of the chest is a useful tool for detecting lung metastases. Also MRI has a role in monitoring the response to chemotherapy and in detecting recurrence. It permits a more accurate study of the tumor volume than other imaging techniques and clinical examination. MRI becomes even more useful when paramagnetic contrast agents are administered because dynamic MRI with contrast enhancement help differentiate postchemotherapy changes from viable tumor--the latter enhancing rapidly and the former slowly. Thus, dynamic MRI allows a precise mapping of any residual tumor activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652509     DOI: 10.1016/s0720-048x(98)00050-3

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  9 in total

Review 1.  A review of imaging of surface sarcomas of bone.

Authors:  Kelly Harper; Paul Sathiadoss; Asif Saifuddin; Adnan Sheikh
Journal:  Skeletal Radiol       Date:  2020-07-17       Impact factor: 2.199

2.  Comparison of plain radiographs and magnetic resonance images in the evaluation of periosteal reaction and osteoid matrix in osteosarcomas.

Authors:  R Dosdá; L Martí-Bonmatí; F Menor; F Aparisi; C Rodrigo; V Ricart
Journal:  MAGMA       Date:  1999-10       Impact factor: 2.310

3.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.

Authors:  Michael Overholtzer; Pulivarthi H Rao; Reyna Favis; Xin-Yan Lu; Michael B Elowitz; Francis Barany; Marc Ladanyi; Richard Gorlick; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

4.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

Review 5.  Review of Osteosarcoma and Current Management.

Authors:  Ryan A Durfee; Maryam Mohammed; Hue H Luu
Journal:  Rheumatol Ther       Date:  2016-10-19

Review 6.  Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

Authors:  Sarah Morice; Geoffroy Danieau; Françoise Rédini; Bénédicte Brounais-Le-Royer; Franck Verrecchia
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

7.  Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?

Authors:  Anne Gomez-Brouchet; Julia Gilhodes; Nathalie Van Acker; Regis Brion; Corinne Bouvier; Pauline Assemat; Nathalie Gaspar; Sebastien Aubert; Jean-Marc Guinebretiere; Beatrice Marie; Frederique Larousserie; Natacha Entz-Werlé; Gonzague de Pinieux; Eric Mascard; Francois Gouin; Pierre Brousset; Marie-Dominique Tabone; Marta Jimenez; Marie-Cecile Le Deley; Jean-Yves Blay; Laurence Brugieres; Sophie Piperno-Neumann; Francoise Rédini
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

8.  Primary bone tumors of adulthood.

Authors:  Harvey E L Teo; Wilfrid C G Peh
Journal:  Cancer Imaging       Date:  2004-03-29       Impact factor: 3.909

Review 9.  SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression.

Authors:  Frédéric Lézot; Isabelle Corre; Sarah Morice; Françoise Rédini; Franck Verrecchia
Journal:  Cells       Date:  2020-02-26       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.